North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers North America Human Insulin Market Trends & Analysis. The Market is Segmented by Drug (basal or Long-Acting Insulin, Bolus or Fast-Acting Insulin, Traditional Human Insulin, Combination Insulin, And Biosimilar Insulin) and Geography (United States, Canada, And Rest of North America). The Value is Provided (in USD) and Volume (in Units) for the Above Segments.

North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

North America Insulin Market Size

View Global Report
North America Human Insulin Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 12.03 Billion
Market Size (2030) USD 14.58 Billion
CAGR (2025 - 2030) 3.91 %
Market Concentration High

Major Players

North America Human Insulin Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of North America Human Insulin Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

North America Insulin Market Analysis

The North America Human Insulin Drugs Market size is estimated at USD 12.03 billion in 2025, and is expected to reach USD 14.58 billion by 2030, at a CAGR of 3.91% during the forecast period (2025-2030).

In North America, the prevalence of diabetes has been steadily increasing, in line with global trends. Sedentary lifestyles, poor dietary choices, and obesity are contributing factors to the rise in both type 1 and type 2 diabetes cases in the region. Consequently, there is a growing need for effective management strategies to tackle this public health issue.

A key element in managing diabetes in North America is the rising utilization of insulin medications. Insulin therapy remains crucial for individuals with type 1 diabetes and many patients with type 2 diabetes who require insulin to maintain optimal blood sugar levels. As the diabetes population continues to grow, the demand for insulin medications is expected to rise in the coming years.

Several factors are propelling the increased use of insulin medications in North America. Advances in insulin formulations and delivery methods have enhanced the effectiveness, safety, and convenience of insulin treatment, making it more attractive to patients. Newer insulin analogs provide quicker onset and longer-lasting effects, allowing for more flexible dosing schedules that closely resemble the body's natural insulin production.

Additionally, the growing awareness of the importance of early intervention and intensive glycemic control in preventing diabetes-related complications has led to more aggressive treatment approaches, including the initiation of insulin therapy at earlier stages of the disease. Healthcare providers are increasingly recognizing the benefits of early insulin initiation in preserving beta-cell function and improving long-term outcomes for patients with diabetes.

Furthermore, initiatives aimed at improving access to insulin, such as patient assistance programs and advocacy efforts to reduce insulin prices, are helping to ensure that individuals with diabetes can afford and access the medication they need. However, challenges such as insulin affordability and healthcare disparities continue to exist and require ongoing attention and action from policymakers, healthcare providers, and stakeholders across North America.

Overall, the increasing diabetes population in North America is driving greater usage of insulin drugs as a crucial component of diabetes management. With continued efforts to improve access, affordability, and innovation in insulin therapy, the region can work towards better outcomes for individuals living with diabetes.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Insulin Industry Overview

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. In the remaining countries, the manufacturers confine themselves to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (insulin glargine).

North America Insulin Market Leaders

  1. Sanofi S.A.

  2. Novo Nordisk A/S

  3. Eli Lilly and Company

  4. Pfizer Inc

  5. Biocon Limited

  6. *Disclaimer: Major Players sorted in no particular order
North America Human Insulin Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

North America Insulin Market News

  • June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy, Lantidra, has been sanctioned by the U.S. Food and Drug Administration. This treatment is derived from pancreatic cells of deceased donors and is intended for individuals with type 1 diabetes. Lantidra is specifically authorized for adults who struggle to achieve target glycated hemoglobin levels due to frequent severe hypoglycemia episodes, despite undergoing intensive diabetes management and education.
  • November 2022: The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control in adults and pediatric patients with diabetes, according to a drug information update from the agency.

North America Insulin Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Basal or Long-acting Insulin
    • 5.1.1.1 Lantus (Insulin Glargine)
    • 5.1.1.2 Levemir (Insulin Detemir)
    • 5.1.1.3 Toujeo (Insulin Glargine)
    • 5.1.1.4 Tresiba (Insulin Degludec)
    • 5.1.1.5 Basaglar (Insulin Glargine)
    • 5.1.2 Bolus or Fast-acting Insulin
    • 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.1.2.2 Humalog (Insulin Lispro)
    • 5.1.2.3 Apidra (Insulin Glulisine)
    • 5.1.2.4 FIASP (Insulin aspart)
    • 5.1.2.5 Admelog (Insulin lispro)
    • 5.1.3 Traditional Human Insulin
    • 5.1.3.1 Novolin/Actrapid/Insulatard
    • 5.1.3.2 Humulin
    • 5.1.3.3 Insuman
    • 5.1.4 Combination Insulin
    • 5.1.4.1 NovoMix (Biphasic Insulin Aspart)
    • 5.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
    • 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
    • 5.1.5 Biosimilar Insulin
    • 5.1.5.1 Insulin Glargine Biosimilars
    • 5.1.5.2 Human Insulin Biosimilars
  • 5.2 Geography
    • 5.2.1 United States
    • 5.2.2 Canada
    • 5.2.3 Rest of North America

6. MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population
  • 6.2 Type 2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk A/S
    • 7.1.2 Sanofi S.A.
    • 7.1.3 Eli Lilly and Company
    • 7.1.4 Biocon Limited
    • 7.1.5 Pfizer Inc.
    • 7.1.6 Wockhardt
    • 7.1.7 Julphar
    • 7.1.8 Exir
    • 7.1.9 Sedico
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi S.A.
    • 7.2.3 Eli Lilly and Company
    • 7.2.4 Other Companies

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North America Insulin Industry Segmentation

Human insulin, such as Myxredlin, Humulin R U-100, and Novolin R, can also be administered intravenously by healthcare professionals in a medical environment. During this process, doctors or nurses will diligently observe any potential side effects. It is important to note that while human insulin effectively manages elevated blood sugar levels, it does not provide a cure for diabetes. The North American human insulin drug market is segmented by drug and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

Drug Basal or Long-acting Insulin Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulin Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulin NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulin Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography United States
Canada
Rest of North America
Need A Different Region or Segment?
Customize Now

North America Insulin Market Research FAQs

How big is the North America Human Insulin Drugs Market?

The North America Human Insulin Drugs Market size is expected to reach USD 12.03 billion in 2025 and grow at a CAGR of 3.91% to reach USD 14.58 billion by 2030.

What is the current North America Human Insulin Drugs Market size?

In 2025, the North America Human Insulin Drugs Market size is expected to reach USD 12.03 billion.

Who are the key players in North America Human Insulin Drugs Market?

Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc and Biocon Limited are the major companies operating in the North America Human Insulin Drugs Market.

What years does this North America Human Insulin Drugs Market cover, and what was the market size in 2024?

In 2024, the North America Human Insulin Drugs Market size was estimated at USD 11.56 billion. The report covers the North America Human Insulin Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Human Insulin Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

North America Insulin Industry Report

Statistics for the 2025 North America Human Insulin Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Human Insulin Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.